First Investment from CMTA’s New Venture Philanthropy Arm
The Charcot-Marie-Tooth Association (CMTA) today announced that it participated in the Seed Series Extension syndicate for Armatus Bio, Inc. (Armatus). Armatus is an emerging biotechnology company that is advancing a unique gene therapy ...
GLENOLDEN, Pa., November 6, 2023 – The Charcot-Marie-Tooth Association announced Nov. 6 that Suzanne (Sue) Bruhn, PhD, an accomplished biotech executive with extensive experience in the development and commercialization of treatments for rare diseases, will take the helm of the ...
“The CMTA welcomes this community update from Novartis and applauds its leading role in the development of treatments for CMT. The CMTA has been maintaining regular contact, providing support and feedback to Novartis during this early transition and integration phase. ...
The Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28 that it has approved a $225,483 award to Dr. Mario Saporta at the University of Miami for a study on the use of antisense oligonucleotides (ASOs) to treat CMT2E.
CMT is ...
This CMT awareness month, the CMTA’s Chief Research Officer, Katherine Forsey, PhD, shares her perspective as a CMT mum and how she navigated her own child’s participation in CMT research.
Charcot-Marie-Tooth disease (CMT) affects the peripheral nerves; the nerves that ...